Market Introduction
The cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are some of the symptoms. Individuals suffering from cardiometabolic syndrome are prone to several other life-threatening diseases such as type 2 diabetes, stroke, coronary artery disease (CAD), cardiovascular disease (CVD), and many others.
Moreover, the increasing prevalence of cardiometabolic diseases is expected to bolster the market growth during the forecast period. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) limits the growth of the Asia Pacific cardiometabolic diseases market.
The supply chain disruptions and the massive demand for efficient treatments for the therapy of COVID-19 have put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures have been taken to control the spread of this pandemic. COVID-19 pandemic has broadly affected those economies in the Asia Pacific region. Countries such as India (31,769,132), Japan (956,407), China (93,289), South Korea (203,926) were adversely affected by the pandemic. The socioeconomics were severely affected, rising in negative inflation, GDPs, and a regional unemployment surge. Recently, patients with both hypertension and obesity have been increasing in Japan. These patients are at exceptionally high risk for severe disease in COVID-19 and thus need careful observation and intensive treatment. Comparable to hypertension, the definition of obesity is not constant among studies/countries, which requires consideration. However, it is essential to note that the therapeutic mechanism of CCB against COVID-19 still awaits further investigation and randomized controlled clinical trials.
Market Overview and Dynamics
The Asia Pacific cardiometabolic diseases market is projected to reach US$ 28,953.2 million by 2028 from US$ 21,091.3 million in 2021; it is anticipated to grow at a CAGR of 4.6% from 2021 to 2028. Cardiometabolic diseases (CMDs) are one of the leading causes of death worldwide. These diseases are mainly caused by an unhealthy lifestyle, physical inactivity, smoking, and an unhealthy diet. CMDs include cardiovascular diseases (CVDs), diabetes mellitus, and chronic renal failure. Most cardiovascular diseases can be prevented by addressing behavioural risk factors, such as tobacco intake, unhealthy dietary choices, obesity, physical inactivity, and alcohol consumption. Diabetes is one of the life-threatening chronic diseases with no functional cure. It leads to various complications and increases the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. There is a rise in the number of people having one or more CMDs due to increasing smoking, lack of exercise, alcohol consumption, and unhealthy food habits. The increasing prevalence of obesity is giving rise to the patient base suffering from CMDs as well. With this rapid upswing in the prevalence of CMDs, the need for appropriate cardiometabolic disease treatments has skyrocketed, resulting in tremendous growth of the Asia Pacific cardiometabolic diseases market.
Key Market Segments
In terms of type, the cardiovascular disease segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of treatment, the ACE inhibitors segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of dosage, the tablet segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of route of administration, the oral segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of end user, the hospital segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. Further, based on distribution channel, the hospital pharmacy segment held the largest market share in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the cardiometabolic diseases market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Eli Lilly and Company., Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Cardax Inc., and Kowa Company, Ltd.
Reasons to Buy Report
ASIA PACIFIC CARDIOMETABOLIC DISEASES MARKET SEGMENTATION
By Country
Companies Mentioned
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 21,091.3 Million |
| Market Size by 2028 | US$ 28,953.2 Million |
| CAGR (2021 - 2028) | 4.6% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Cardiometabolic Diseases Market is valued at US$ 21,091.3 Million in 2021, it is projected to reach US$ 28,953.2 Million by 2028.
As per our report Asia Pacific Cardiometabolic Diseases Market, the market size is valued at US$ 21,091.3 Million in 2021, projecting it to reach US$ 28,953.2 Million by 2028. This translates to a CAGR of approximately 4.6% during the forecast period.
The Asia Pacific Cardiometabolic Diseases Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Cardiometabolic Diseases Market report:
The Asia Pacific Cardiometabolic Diseases Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Cardiometabolic Diseases Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Cardiometabolic Diseases Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Cardiometabolic Diseases Market
